Abstract. MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides that can function as oncogenes or tumor suppressors in human cancer. Downregulation of the miRNA miR-133a in many type of cancers, and a reduction of cell proliferation, migration, and invasion upon over-expression, suggests that miR-133a is a tumor suppressor. In this study, genome-wide gene expression analysis of HNSCC cells that over-express miR-133a showed that caveolin-1 (CAV1), a multifunctional scaffolding protein, is down-regulated, a result that was confirmed by real-time PCR and Western blot analysis. A luciferase reporter assay revealed that miR-133a is directly bound to CAV1 mRNA. Cancer cell migration and invasion were significantly inhibited in HNSCC cells transfected with si-CAV1. Therefore, CAV1 functions as an oncogene in HNSCC. The identification of tumor suppressive miRNAs and their target genes could provide new insights into potential mechanism of HNSCC carcinogenesis.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs with a length of approximately 22 nucleotides. They regulate gene expression by mRNA cleavage and at the post-transcriptional level by translational suppression (1) . They play important roles in various biological and metabolic processes, including development, differentiation, signal transduction, cell maintenance, and cancer (1, 2) . Bioinformatic predictions indicate that miRNAs regulate more than 30% of the protein coding genes (3) . It is estimated that approximately 1,000 miRNAs exist in the vertebrate genome. So far, 1048 human miRNAs are registered at miRBase release 16.0 (http://microrna.sanger. ac.uk/).
An important role for miRNAs in the development of cancer has emerged in recent years (4) . They are aberrantly expressed in many human cancers, and may function as oncogenes and tumor suppressors. A growing body of evidence indicates that unique miRNA expression profiles associated with particular cancers could serve as useful biomarkers for disease diagnosis and prognosis (5) (6) (7) . Studies have been carried out for the purpose of identifying specific miRNA alterations in various cancers, including head and neck squamous cell carcinoma (HNSCC) (8) (9) (10) .
Down-regulated miRNAs, including miR-133a, have been identified in bladder cancer and esophageal squamous cell carcinoma (ESCC) (11, 12) . Down-regulation of miR-133a has also been reported in HNSCC, and oral and colorectal cancers (7, 13, 14) . The finding that over-expression of miR-133a reduces cell proliferation, migration and invasion suggested that miR-133a is a tumor suppressor (12, 15) . In this study, a screen for miR-133a target genes was performed using genome-wide expression analysis on HNSCC cell lines (HSC3 and SAS) transfected with miR-133a. Among the downregulated genes, caveolin-1 (CAV1) contained predicted binding sites for miR-133a.
Caveolins are a class of oligomeric structural proteins that are both necessary and sufficient for caveolae formation. Caveolae are 50-to 100-nm ˆ-shaped invaginations of the plasma membrane that function as regulators of signal transduction. CAV1 regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell migration and metastasis, cell death and survival, multidrug resistance and angiogenesis (16, 17) .
A luciferase reporter assay was used to determine if CAV1 actually has miR-133a target sites. The functional significance of CAV1 in HNSCC was also investigated using a loss-offunction assay. This is the first report that oncogenic CAV1 is directly controlled by tumor suppressive microRNA, miR-133a, in HNSCC.
Materials and methods
Clinical HNSCC specimens and HNSCC cell culture. Twentyfive pairs of primary HNSCC (oral cavity 11, larynx 3, oropharynx 5, and hypopharynx 6) and corresponding normal epithelial samples were obtained from patients in Chiba University Hospital (Chiba, Japan) from 2007 to 2009. All tissue specimens were obtained from patients undergoing surgical treatment. Normal tissues were obtained far from the center of the cancer in surgical specimens. No cancer cells were detected in neighboring formalin-fixed paraffin-embedded tissues. Written consent of tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University. The specimens were immersed in RNAlater (Qiagen, Valencia, CA, USA) and stored at -20˚C until RNA was extracted. Human HNSCC cell lines (HSC3; derived from lymph node metastasis of tongue squamous cell carcinoma and SAS; derived from primary lesion of tongue squamous cell carcinoma) were provided by the American Type Culture Collection (ATCC, Manassas, VA, USA). Both cell lines were grown in Dulbecco's modified Eagle's medium/ nutrient mixture F-12 Ham (DMEM/F-12) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37˚C.
RNA isolation. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA concentrations were determined spectrophotometrically, and molecule integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Mature miRNA transfection and small interfering RNA treatment. Mature miRNA molecules, Pre-miR™ miRNA precursors (hsa-miR-133a; P/N: AM17100 and negative control miRNA; P/N: AM17111), small interfering RNA, Silencer ® Select siRNA; si-CAV1 (P/N: s2446 and s2448) (Applied Biosystems, Foster City, CA, USA) and negative control siRNA (D-001810-10; Thermo Fisher Scientific, Waltham, MA, USA) were incubated with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax reagent (Invitrogen) as described previously (11) . Transfection efficiency of Pre-miR in cell lines was confirmed based on down-regulation of PTK9 mRNA following transfection with miR-1 (as recommended by the manufacturer).
Cell proliferation, migration and invasion assays. Cells were transfected with 10 nM siRNA by reverse transfection and plated into 96-well plates at 3x10 3 cells per well. After 72 h, cell proliferation was determined by the XTT assay, using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) (12, 18) . Triplicate wells were measured for cell viability in each treatment group.
Cell migration activity was evaluated using a woundhealing assay. Cells were plated in 6-well dishes, and the cell monolayer was scraped using a micropipette tip. The initial gap length (0 h) and the residual gap length, 24 h after wounding were calculated from photomicrographs (15) .
A cell invasion assay was carried out using modified Boyden Chambers containing transwell-precoated matrigel membrane filter inserts with 8-μm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA) (15) . All experiments were performed in triplicate.
Target gene search for miR-133a.
A genome-wide screen using miR-133a transfectants was performed to identify target genes of miR-133a in two HNSCC cell lines, HSC3 and SAS. Oligomicroarray Human 44K (Agilent Technologies) was used for expression profiling in the transfectants in comparison with a miRNA-negative-control transfectant (12, 15, 18) . Hybridization and wash steps were performed as previously described (19) . The arrays were scanned using a Packard GSI Lumonics ScanArray 4000 (Perkin-Elmer, Boston, MA, USA). The data were analyzed by means of DNASIS array software (Hitachi Software Engineering, Tokyo, Japan), which converted the signal intensity for each spot into text format. The Log 2 ratios of the median subtracted background intensity were analyzed. Data from each microarray study were normalized by a global normalization method (19) .
Predicted target genes and their target miRNA binding site seed regions were investigated using TargetScan (release 5.1, http://www.targetscan.org/). The sequences of the predicted mature miRNAs were confirmed using miRBase (release 16.0, http://microrna.sanger.ac.uk/).
Real-time quantitative RT-PCR.
First-strand cDNA was synthesized from 1 μg total RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene-specific PCR products were assayed continuously using a 7900-HT Real-Time PCR System according to the manufacturer's protocol. The initial PCR step consisted of a 10-min hold at 95˚C, followed by 40 cycles of a 15-sec denaturation at 95˚C and a 1-min annealing/extension at 63˚C. TaqMan ® probes and primers for CAV1 (P/N: Hs00971716_m1) and the GAPDH (A/N: NM_002046) internal control were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The expression levels of miR-133a (P/N: 002246) were analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to RNU48 (A/N: X96648). All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.
Immunoblotting. Cells were harvested 72 h after transfection and lystaes were prepared. Protein lysate (50 μg) was separated by NuPAGE on a 4-12% bis-tris gel (Invitrogen) and transferred to PVDF membranes. Immunoblotting was performed with diluted (1:100) monoclonal CAV1 antibody (ab17052, Abcam, Cambridge, UK), with ß-actin antibody (sc-1615; Santa Cruz Biotechnology, Santa Cruz, CA, USA) used as an internal control. The membrane was washed and incubated with goat anti-mouse IgG (H+L)-HRP conjugate (Bio-Rad, Hercules, CA, USA). Specific complexes were visualized by echochemiluminescence (GE Healthcare BioSciences, Princeton, NJ, USA).
Plasmid construction and dual-luciferase assay. miR-133a
target sequences were inserted between the XhoI and PmeI restriction sites in the 3'UTR of the hRluc gene in the psiCHECK-2 vector (Promega, Madison, WI, USA). The amplified fragment was cloned into the psiCHECK-2 vector and confirmed by sequencing using the following primers: 5'-ACCGAGTTCGTGAAGGTGAA-3' and 5'-CAAACCCT AACCACCGCTTA-3'. SAS cells were then transfected with 5 ng vector, 10 nM mature miRNA molecules, Pre-miRNA™ miR-133a (Applied Biosystems), and 1 μl Lipofectamine 2000 (Invitrogen) in 100 μl Opti-MEM™. Firefly and Renilla luciferase activities in cell lysates were determined using a dual-luciferase assay system (Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities.
Statistical analysis. The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the non-parametric Mann-Whitney's U test or the paired t-test. The relationship among three variables and numerical values was analyzed using the Bonferroni-adjusted Mann-Whitney's U test; a non-adjusted statistical level of significance of P<0.05 corresponded to a Bonferroni-adjusted level of P<0.0167. All analyses were performed using Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA).
Results

Identification of miR-133a target genes by genome-wide expression analysis.
To investigate the molecular basis of candidate targets of miR-133a in HNSCC cells, we examined the effect of miR-133a on protein-coding genes. Mature miR-133a was transiently transfected into HSC3 and SAS cells, with negative-miRNA transfection used as a control. Comprehensive gene expression analysis (see Materials and methods) clearly showed changes in gene expression patterns between miR-133a and negative-control transfectants. To identify candidate miR-133a target genes, a cut-off of values less than -2.00-fold was applied to the array data. This filtering resulted in the identification of 164 genes that were significantly down-regulated upon miR-133a transfection both HSC3 and SAS cells (top 25 genes were shown; Table I ). Entries from the microarray data were approved by the Gene Expression Table I . Top 25 genes down-regulated less than -2.00-fold in miR-133a transfectants. 1  Male  60  Oral  Well  2  0  0  II  2  Male  60  Oral  Moderate  4a  2c  0  IV A  3  Male  66  Oral  Moderate  2  0  0  II  4  Female  73  Oral  Well  1  0  0  I  5  Male  64  Oral  Well  1  0  0  I  6  Male  66  Oral  Well  3  0  0  III  7  Male  58  Oral  Moderate  1  0  0  I  8  Male  65  Oral  Moderate  4a  1  0  IV A  9  Male  73  Oral  Poor  3  1  0  III  10  Female  38  Oral  Well  2  2b  0  IV A  11  Male  67  Oral  Moderate  4a  2c  0  IV A  12  Male  66  Larynx  Well  4a  0  0  IV  13  Male  69  Larynx  Well  3  0  0  III  14  Male  57  Larynx  Moderate  4a  0  0  III  15  Male  64  Oropharynx  Poor  3  2c  0  IV A  16  Male  77  Oropharynx  Moderate  4b  2b  0  IV B  17  Male  76  Oropharynx  Poor  2  0  0  II  18  Male  52  Oropharynx  Moderate  3  2a  0  IV A  19  Female  65  Oropharynx  Well  4a  2b  0  IV A  20  Female  65  Hypopharynx  Well  4a  0  0  IV A  21  Male  68  Hypopharynx  Poor  4a  1  0  IV A  22  Male  68  Hypopharynx  Moderate  4a  1  0  IV A  23  Male  61  Hypopharynx  Moderate  4a  2c  0  IV A  24  Male  66  Hypopharynx  Moderate  2  2c  0  IV A  25  Female  74  Hypopharynx  Well  4a  0  0  IV A ----------------------------------------------------------------------------------------------------- Omnibus (GEO), and were assigned the GEO accession number GSE20028.
.89 ------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
No. Gender Age Location Differentiation T N M Stage -
----------------------------------------------------------------------------------------------------
The 3'UTR regions of these down-regulated genes were examined for miR-133a target sites using the TargetScan database. Of the top 25 putative gene targets, 9 genes contained miR-133a target sites.
CAV1 mRNA and miR-133a expression in HNSCC clinical
specimens. The expression level of CAV1 mRNA was upregulated in clinical HNSCC specimen compared with adjacent normal tissues (Fig. 1A) . CAV1 mRNA expressions in HNSCC cell lines were also over-expressed relative to normal epithelia (Fig. 1B) . Conversely, miR-133a was down-regulated in tumor tissues (Fig. 1C) . Characteristic data of 25 HNSCC patients are described in Table II. CAV1 as a target of post-transcriptional repression by miR133a. CAV1 was the third-ranked candidate gene in the genome-wide gene expression analysis. We focused on CAV1, not first-or second-ranked genes, because the latter were not reported in association with HNSCC.
The expression level of CAV1 mRNA was significantly decreased in the two HNSCC cell lines (HSC3 and SAS) transfected with miR-133a (Fig. 2A) . The protein expression level was also markedly reduced in miR-133a transfectants (Fig. 2B) . SAS cells were used to determine the effect of miR-133a suppression on CAV1 expression. The TargetScan database identified two putative target sites in the 3'UTR of CAV1 (Fig. 3, upper) . A luciferase reporter assay confirmed the 3'UTR of CAV1 as the actual target of miR-133a. Luciferase activity was significantly decreased in two miR-133a target sites (position 735-741 and 888-894 in 3'UTR of CAV1) (Fig. 3, lower) .
Effect of CAV1 silencing on cell proliferation, migration and invasion activity in HNSCC cell lines.
A loss-of-function assay using siRNA analysis was performed to examine the oncogenic function of CAV1 in the presence of miR-133a. We determined whether si-CAV1 reduced both mRNA and protein expression levels of si-CAV1 transfectants in HNSCC cell lines, HSC3 and SAS. CAV1 mRNA and protein were reduced following a 72-h transfection with si-CAV1 (Fig. 4) . The XTT assay revealed no significant cell growth inhibition in the si-CAV1 transfectants compared with siRNA control transfectants (Fig. 5A) . The wound healing assay demonstrated that cell migration was inhibited by si-CAV1 (% of wound closure; control: 100.0±8.1, si-CAV1-1: 68.4±4.1, si-CAV1-2: 59.7±5.9, Fig. 5B ), and the matrigel invasion assay showed that the number of invading cells was significantly decreased in si-CAV1 transfectants (invading cell numbers; control: 230.3±20.7, si-CAV1-1: 176.2±15.4, si-CAV1-2: 47.1±4.9, Fig. 5C ).
Discussion
Aberrant expression of miRNAs has been associated with the development of various cancers. To date, studies have been carried out for the purpose of identifying specific miRNA alterations in various cancers, including HNSCC (8) (9) (10) . Recently, we reported several down-regulated miRNAs have been found in the expression signatures of bladder cancer and ESCC (11, 12) . Expression studies revealed a reduction in miR-133a levels in many types of cancers (7, (11) (12) (13) (14) (20) (21) (22) . Consistent with these earlier studies, we found significant inhibition of cell growth, migration and invasion in ESCC and bladder cancer cell lines transfected with miR-133a (12, 15) . These results strongly suggest that miR-133a functions as a tumor suppressor. Consequently, we focused on miR-133a and continued the analysis of the molecular mechanism of miR-133a and HNSCC oncogenesis.
A new class of regulatory molecules known as miRNAs is redefining our understanding of the molecular pathways associated with carcinogenesis. Bioinformatic predictions indicate that miRNAs regulate more than 30% of the protein coding genes (3). We adopted a method of genome-wide gene expression analysis using specific miRNA transfectants and searched for targets of miR-133a in HNSCC cell lines. Using this strategy in several cancer cell lines led to the identification of tumor suppressive miRNA targets (12, 15, 23) . CAV1 was significantly down-regulated by miR-133a over-expression in HNSCC cell lines. The luciferase reporter assay revealed that CAV1 contains sites targeted by miR-133a. This is the first report that tumor suppressive miR-133a directly regulates CAV1 in cancer cells. Published articles of miR-133a targets include miR-133a inhibited proliferation and induced apoptosis in SCC of the tongue, and directly controlled pyruvate kinase type M2 expression (20) . A search for tumor suppressive miRNA targets is important for elucidation of the molecular network of HNSCC progression, to which our expression signature of miR-133a target analysis will contribute.
Caveolins are a basic constituent of ˆ-shaped cell membrane microdomains called caveolae. Several heterogeneous functions are attributed to caveolae and their proteins, including vesicular transport and cholesterol homeostasis (17, 24) . A scaffolding amino acid sequence identified in CAV1 allows this protein to interact with signaling molecules such as epidermal growth factor receptor, G-proteins, c-Src-like kinases, HA-Ras, protein kinase C, endothelial nitric-oxide synthase, and integrin (16, (25) (26) (27) . In fact, in several types of cancer cells, CAV1 has been associated and/or co-localized with epidermal growth factor receptor (EGFR) and modulate EGFR signaling (28, 29) . In A549 lung cancer cells, EGFR and CAV1 co-localize in the cell membrane, where CAV1 may have a role in carcinogenesis via EGFR activation, transport to its perinuclear location, and activation maintenance (30, 31) .
Over-expression of CAV1 has been reported in nasopharyngeal cancer, ESCC, urological cancer, prostate cancer and gliomas. Up-regulation of CAV1 is associated with more aggressive behavior, increased recurrence rate and poorer prognosis (32) (33) (34) (35) (36) . Increased CAV1 expression has recently been reported in multidrug-resistant neoplastic cells, suggesting its specific role in the acquisition and maintenance of this phenotype (37, 38) . In this study, a loss-of-function study using si-CAV1 in HNSCC cell lines revealed that CAV1 mediates cell migration and invasion. In contrast, CAV1 appears to be a suppressor of metastatic breast cancer when expression is inhibited (39, 40) . In HNSCC cell lines, over-expression of CAV1 may play an inhibitory role in carcinogenesis and lung metastasis through regulation of integrin ß1-and Src-mediated cell-cell and cell-matrix interactions (41) . CAV1 expression has been studied in several cancers, in which expression patterns were either reduced, up-regulated or unchanged; therefore, its role in cancer is still debated and highly controversial (17, 24, 42) . Further analysis of the downstream signaling pathways of CAV1 in different cancer cell types is needed to solve these contradictions.
Epithelial to mesenchymal transitions (EMT) are critical for the invasion, progression, and metastasis of epithelial carcinogenesis. Cancer cells that undergo EMT, acquire various types of malignant ability, such as invasion and metastasis to lymph node or distant organ (43, 44) . However, the role of EMT in HNSCC remains unexplored. Overexpression of CAV1 during EMT showed tight regulation by focal adhesion kinase (FAK). It also demonstrated that FAKmediated CAV1 up-regulation was involved in cell adhesion and motility (44) .
How CAV1 expression changes in many types of cancers is still unclear, but one possible mechanism is through regulation by miRNAs. Loss of miR-133a, an endogenous CAV1 inhibitor, may promote aberrant expression of CAV1 in cancer cells, including HNSCC, contributing to pathogenesis and cancer progression. Down-regulation of miR-133a and over-expression CAV1 were identified in HNSCC, which suggests that this tumor suppressive miRNA and oncogenic mRNA pathway may be an important therapeutic target for human cancers.
